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ABSTRACT
Background Scleritis is a potentially blinding
inﬂammatory disorder. Standard care consists of
systemic corticosteroids and immunosuppresants. The
authors describe a series of 10 patients suffering from
scleritis treated with the TNF inhibitor inﬂiximab because
this scleritis was refractory to standard therapy.
Methods The authors reviewed the medical records of
patients with scleritis at the Massachusetts Eye
Research and Surgery Institution, treated with inﬂiximab.
All cases had non-infectious scleritis refractory to
traditional immunomodulatory therapy and received
5 mg/kg of inﬂiximab at 4e8-weekly intervals. The main
outcome measures evaluated were clinical response,
reduction in concomitant immunomodulatory therapy and
adverse effects. Inﬂammation control and visual acuity
were assessed using life-table methods.
Results A favourable clinical response to inﬂiximab was
seen in 100% of the patients, with six (60%) of them
achieving remission and cessation of concomitant
immunosuppression. A clinical response to inﬂiximab
therapy occurred within 13.24 weeks on average. Based
on clinical response, the authors found that repeat
monthly infusions were required to maintain remission.
One (10%) patient developed a lupus-like reaction
necessitating discontinuation of inﬂiximab.
Conclusion Inﬂiximab may be considered in the
treatment of non-infectious scleritis refractory to other
treatment.
BACKGROUND
Scleral inﬂammation is associated with systemic
autoimmune disorders in 50% of cases, and is often
associated with signiﬁcant morbidity.
1 Ocular
complications include keratitis, uveitis, and glau-
coma with anterior scleritis and exudative detach-
ments or other posterior segment complications
with posterior scleritis.
12Immunosuppressive
therapy has proved to be successful in the treat-
ment of autoimmune disorders.
34Inﬂiximab,
a humanised, chimeric monoclonal antibody
directed against the proinﬂammatory cytokine
tumour necrosis factor a (TNF-a), has been
approved and marketed for the treatment of rheu-
matoid arthritis and Crohn disease.
56While there
have been reports of the efﬁcacy of inﬂiximab in the
treatment of uveitis, there is little known about the
efﬁcacy and tolerability of inﬂiximab for the treat-
ment of scleritis. We review our experience with
this drug in the treatment of scleritis refractory to
conventional treatment.
METHODS
The medical records of 10 patients with scleritis
who received inﬂiximab (Remicade, Centocor,,
Horsham, Pennsylvania) from September 2003 to
October 2007 were reviewed. All of the patients
were seen by the same physician (CSF). Scleritis
was deﬁned as oedema in the episcleral and scleral
tissues with both superﬁcial and deep episcleral
vessel injection accompanied by pain and tender-
ness to palpation. It was classiﬁed as anterior
(diffuse, sectoral or necrotising) or posterior, as
proposed by Watson and Hayreh.
7 Posterior scleritis
was diagnosed on the basis of clinical and ultraso-
nography ﬁndings. Scleritis was graded and scored
according to the grading system deﬁned by Foster
and Vitaledsclera injection and inﬂammation 0 to
4 in 0.5 gradations; these ﬁndings were documented
by drawings, photography or both.
Treatment with inﬂiximab was considered on an
off-label basis after failure of alternative immuno-
suppression. Inﬂiximab was initiated as 5 mg/kg
infusions over 120 min (180 min for the ﬁrst
infusion). A loading dose was infused at zero and
2 weeks, and then maintenance therapy was
administered at intervals of approximately 1 month.
The intervals between infusions and dose of inﬂix-
imab were adjusted depending on disease activity
and tolerance of the medications. Ophthalmic
assessment was performed every 4e6 weeks. Serum
biochemical and haematological proﬁles were
monitored at each clinic visit. Remission was deﬁned
as control of inﬂammation while on inﬂiximab
therapy without use of corticosteroid therapy.
Outcome variables evaluated included inﬂam-
mation recurrence, treatment response and decrease
in ocular and systemic adjuvant therapy.
Statistical analysis was performed using PROC
LIFETEST in PC_SAS (version 6.08; SAS Institute,
Cary, North Carolina). Because eyes were not
examined independently and because disease
progression and response to therapy are highly
correlated between eyes, the data for left and right
eyes were analysed separately.
RESULTS
The clinical data for each patient are summarised in
table 1. The ocular diagnoses included diffuse
scleritis (n¼4), nodular scleritis (n¼2), sclerouveitis
(n¼2) and scleritis associated with keratitis (n¼2).
Seven patients had underlying systemic diag-
noses, which included rheumatoid arthritis, Crohn
disease and Behçet disease.
The mean patient age was 51.1611.4 (range 35
to 70). The mean number of inﬂiximab infusions
was 16.266.0 (range 7 to 24), and the mean follow-
up time while on inﬂiximab was 16.4 months
(range 6e48). Nine patients received inﬂiximab
primarily for treatment of scleritis, whereas patient
no 6 received inﬂiximab primarily for control of
uveitis associated with scleritis.
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Clinical scienceThe medications in table 1 reﬂect all IMT regimes used prior
to inﬂiximab therapy. Lifetime tables for control of inﬂamma-
tion are reported in table 2, and visual acuity in table 3.
Case reports
Patient 1 had a long history of Crohn disease with bilateral scle-
rouveitis, cystoid macular oedema and open-angle glaucoma. This
patient had initially been treated with chlorambucil which had
been discontinued due to leucopenia, and subsequently with
mycophenolate mofetil with sirolimus, which proved inadequate
for control of ocular inﬂammation. A marked clinical improve-
ment occurred within days of the ﬁrst inﬂiximab infusion.
Mycophenolate mofetil and sirolimus were coadministered to
maintain remission of inﬂammation. The patient underwent
bilateral glaucoma surgeries and unilateral cataract surgery while
on this combination with no reactivation of scleritis post-
operatively.
Patient 2 with Crohn disease initially presented with right eye
(OD) pain, redness and photophobia. The patient was diagnosed
to have nodular scleritis and was treated with subconjunctival
triamcinolone acetonide 4 mg and oral Prednisone on a gradual
taper. After an initial improvement, the symptoms recurred
2 months following steroid taper. There was no clinical
improvement with oral diclofenac, and the patient developed
fatigue and leucopenia following treatment with mycopheno-
late mofetil, which was therefore discontinued. Chlorambucil
along with topical prednisolone acetate eye-drops were insti-
tuted, but the patient continued to have pain in the right eye
and developed new symptoms in the left eye (OS). Chol-
rambucil 6 mg/day was started becasue of prior failed treat-
ments with good clinical response, though the dosage needed to
be reduced to 2 mg every alternate day due to leucopenia. This
dosage proved to be inadequate for control of ocular inﬂamma-
tion, and a decision to add inﬂiximab was made. The patient’s
leucocyte count initially rose but subsequently fell on this
regime, necessitating discontinuation of chlorambucil. Inﬂix-
imab was withheld, as the liver function tests were noted to be
abnormal. The patient was evaluated and diagnosed as having
rheumatoid arthritis with possible autoimmune hepatitis. Liver
biopsy was inconclusive, and inﬂiximab therapy was resumed.
The ocular inﬂammation and arthritis-related symptoms are
currently in control with 4-weekly infusions of inﬂiximab.
Patient 3 had a history of rheumatoid arthritis-associated
bilateral diffuse anterior scleritis treated with azathioprine and
chlorambucil in the past and uncontrolled while on subcuta-
neous methotrexate. The patient responded well to monthly
infusions of inﬂiximab with resolution of ocular and joint-
related symptoms. After 12 infusions, the patient developed
a rash with antinuclear antibody (ANA) titres of 1:640 and skin
biopsy-proven systemic lupus erythematosus (SLE). Inﬂiximab
was therefore discontinued. On treatment with mycophenolate
mofetil, the patient developed nausea, fatigue and gastritis, and
raised erythrocyte sedimentation rate with normal blood counts
and liver function tests. We suspected a reactivation of SLE, and
the patient was referred for evaluation but subsequently lost to
follow-up.
Patient 4 was diagnosed as having rheumatoid arthritis and
Crohn disease with bilateral diffuse scleritis and unilateral
peripheral ulcerative keratitis. The patient reported recurrent
episodes of scleritis while on oral diclofenac and topical
prednisolone acetate necessitating frequent intravenous corti-
costeroid infusions. In an attempt to achieve control with
a steroid-sparing regime, 4-weekly infusions of inﬂiximab were
started. Suboptimal resolution of symptoms led us to add
weekly subcutaneous methotrexate (20 mg) injections. After
4 months, resolution of inﬂammation was achieved and has
been maintained since. The patient has been controlled on this
regime in the absence of systemic or topical corticosteroids.
Patient 5, with Crohn disease and bilateral sclerouveitis with
interstitial keratitis, was inadequately controlled with oral
prednisone and topical prednisolone acetate. An intravenous
course of methylprednisone for 3 days was administered, with
topical prednisolone acetate eye-drops, concomitant to a regime
of 4-weekly inﬂiximab while tapering off the oral prednisone.
Following a mild reactivation of inﬂammation (trace injection
OU) noted after 9 months of treatment, during a reportedly
stressful period, the patient is currently well controlled on
monthly inﬂiximab infusions.
Patient 6, on subcutaneous methotrexate for rheumatoid
arthritis, had a history of bilateral sclerouveitis. Methotrexate
had recently been increased to 25 mg/week with the addition of
oral prednisone 5 mg for control of her joint symptoms. Despite
this therapy, the patient’s symptoms persisted and were
accompanied by an increase in ocular pain. We noted scleral
inﬂammation and anterior uveitis OS. Topical prednisolone was
started along with inﬂiximab, in addition to prior therapy. While
the ocular pain and scleritis resolved, the patient noted repeated
reactivation of anterior uveitis on this regime necessitating
episodic topical predisolone acetate to keep the associated
anterior uveitis in check.
Patient 7 had bilateral nodular scleritis, uncontrolled initially
on mycophenolate mofetil and subsequently on cyclophospha-
mide. The patient was started on monthly inﬂiximab infusions.
The infusions had to be temporarily withheld due to develop-
ment of herpes zoster 3 months after initiating inﬂiximab,
which was treated with oral valacyclovir. Inﬂiximab therapy
was resumed after a month and took 9 months for achieving
control of inﬂammation with the concomitant use of diﬂunisal.
Patient 8 developed bilateral diffuse anterior scleritis which
had in the past been unresponsive to a combination of subcu-
taneous methotrexate with oral prednisone 5 mg. Following
this, replacement of methotrexate with mycophenolate mofetil
was attempted in vain. Ciclosporin A had been added and later
Table 3 Life table estimate of visual acuity change
Minus 1
line
Minus 2
lines Plus 1 line Plus 2 lines
Follow-up (months) OD OS OD OS OD OS OD OS
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 0.00 0.00 0.00 0.00 0.20 0.20 0.00 0.00
6 0.11 0.00 0.00 0.00 0.20 0.20 0.00 0.00
12 0.11 0.00 0.00 0.22 0.20 0.20 0.00 0.00
OD, right eye; OS, left eye.
Table 2 Life-table estimate of relapse occurrence
Follow-up month Relapse rate
00
3 0.0
6 0.11
9 0.22
12 0.34
15 0.63
18 0.63
21 0.63
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Clinical sciencewithdrawn due to raised liver enzymes. Subsequent therapy had
included intravenous methyl prednisone, regional triamcinolone
acetonide and oral prednisone. A month later, ocular symptoms
recurred, and we instituted a regime of intravenous metho-
trexate 50 mg with methylprednisone 1000 mg while we
obtained insurance approval for inﬂiximab therapy. The patient
responded well to inﬂiximab infusions administered 4-weekly
with control of ocular inﬂammation, except for one episode of
reactivation following a missed dose of inﬂiximab. While on
inﬂiximab, the patient underwent cataract surgery with no
reactivation of inﬂammation postoperatively, and is currently
well controlled on this regime.
Patient 9 had a history of bilateral nodular scleritis unre-
sponsive initially to methotrexate and later cyclophosphamide.
The patient responded well to inﬂiximab therapy, initially at 4-
weekly intervals. Topical prednisolone acetate was tapered over
the initial 3 months. After 1 year of monthly inﬂiximab 400 mg
infusions, we gradually reduced the dosage and were eventually
able to wean the patient off inﬂiximab over a period of 2.5 years.
The patient is off all systemic and topical medication with no
activation of inﬂammation.
Patient 10 had a history of unilateral anterior scleritis OS,
dependent on corticosteroid therapy. The patient was HLA-B51-
positive and was diagnosed as having Behçet disease, using the
1990 International criteria. The patient was initially unsuc-
cessfully treated with oral celecoxib, mycophenolate mofetil and
subsequently methotrexate. The patient achieved symptomatic
relief with subcutaneous methotrexate and oral prednisone but
needed to change therapy to chlorambucil due to side effects.
With this new agent, we were able to discontinue oral predni-
sone, but the patient developed leucopenia and unresolving
pharyngitis. Two months later, the patient presented with
uncontrolled ocular inﬂammation and joint pain, for which
three infusions of 50e100 mg intravenous methotrexate
combined with 1 g of intravenous methyl prednisolone were
administered while obtaining insurance approval for inﬂiximab
therapy. The patient was initially treated with 300 mg infusions
every 4 weeks and was steroid-free, and without inﬂammation,
for 4 months. Joint pain and mouth ulcers resolved after initia-
tion of inﬂiximab. The patient missed one infusion and devel-
oped mild eye pain and injection that resolved with combined
infusion of inﬂiximab 300 mg and 1 g of methylprednisolone.
The patient did not need additional steroid therapy after this
episode and reports no side effects while on inﬂiximab. The
patient is currently well-controlled on 6-weekly inﬂiximab
infusions.
DISCUSSION
Inﬂiximab, a monoclonal antibody to TNF-a, is a novel immu-
nomodulatory agent which has proven to be effective in a number
of autoimmune diseases, in particular Crohn disease, rheumatoid
arthritis, psoriasis and systemic vasculitis.
5 689Its use in the
treatment of scleritis has been reported in a small number of
patients.
10 11 This report describes a relatively large case series of
patients with scleritis to be treated with inﬂiximab.
A favourable response to inﬂiximab was seen in 90% of the
patients, with six (60%) of them achieving remission and
cessation of concomitant immunosuppression. A clinical
response to inﬂiximab therapy occurred within 13.24 weeks on
average. Based on clinical response, we found that repeat
monthly infusions were required to maintain remission.
Eight (80%) patients continue to receive inﬂiximab therapy on
a regularly scheduled basis. The appropriate length of treatment
for these patients is unclear and may be indeﬁnite. Life-table
analysis further supports the efﬁcacy of inﬂiximab for control-
ling ocular inﬂammation.
One patient (patient 9) with idiopathic nodular scleritis had
inﬂammation resolution after 24 infusions and has remained
relapse-free without IMT for 27 months. While biological ther-
apies such as inﬂiximab are generally felt not to be curative, it is
possible some patients may achieve durable remission without
the need for ongoing treatment.
One patient (patient 4) who initially had inﬂammation
recurrence while receiving inﬂiximab therapy required the
addition of methotrexate with good inﬂammation control
thereafter. In two patients (patients 1 and 6) we were unable to
reduce concomitant immunomodulatory therapy. In ﬁve
patients (patients 2, 7, 8, 9 and 10), we were able to stop
concomitant systemic immunomodulatory medication with
successful control of inﬂammation.
One patient (patient 6) had persistant uveitis with resolution
of scleral inﬂammation while on inﬂiximab, necessitating the
use of prednisolone acetate topically.
Two patients underwent cataract or glaucoma surgery with
no exacerbation of scleritis postoperatively. In each instance,
ocular surgery was timed to occur within a week of inﬂiximab
administration. Postoperative topical medications were as
prescribed after routine ocular surgeries.
Two patients developed streptococcal upper respiratory
infection while on inﬂiximab, necessitating cessation of therapy
until resolution with antibiotics was achieved.
In contrast with the recent ﬁnding of a relatively high rate of
adverse events in a prospective trial of inﬂiximab therapy,
12 our
review included only one adverse event necessitating therapy
discontinuation. Other studies have shown low rates of adverse
events similar to those in our report. Drug-induced lupus reac-
tion is the one signiﬁcant adverse event that we observed; this
has been previously reported in the ophthalmic and rheumato-
logical literature with use of inﬂiximab.
13 All the reported cases
of lupus-like syndrome have improved with therapy discontin-
uation. Another patient (patient 2) developed possible autoim-
mune hepatitis which was not conﬁrmed, and liver function was
subsequently normal after resuming therapy with inﬂiximab.
Autoimmune hepatitis has been noted to occur with a lupus-like
reaction to inﬂiximab.
14
Five of our patients are continuing to receive inﬂiximab
therapy without any concomitant IMT. Typically, patients are
maintained on low-dose immunosuppressive therapy to prevent
antibody production to inﬂiximab. The patients who opted for
monotherapy were all informed of possible risks. Their desire to
avoid immunosuppressive therapy and their good inﬂammation
control while taking inﬂiximab led them to make this choice. All
these patients have maintained an excellent response to inﬂix-
imab therapy, having received between two and 22 infusions.
Monotherapy may be offered to patients with scleritis and may
be efﬁcacious over the long term.
In our experience, the optimal maintenance inﬂiximab dosing
interval for patients with scleritis is shorter than the 8 weeks
that has been reported for patients with diseases such as Crohn
disease,
15 and is usually 4 weeks. We have found that every-
month dosing in these patients is well tolerated and eliminates
‘escape’ of inﬂammation between treatments.
Inﬂiximab is a highly targeted therapy with a rapid action
that avoids many of the adverse effects associated with other
immunosuppressive agents. Furthermore, immunosuppressants
that target T cell activation, such as ciclosporin A and myco-
phenolate mofetil, may act synergistically with inﬂiximab,
because they target the T cell effector response through
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include short duration of effect and its high cost.
All 10 of these patients with scleritis had inﬂammation
control while taking inﬂiximab and may be a subgroup of
patients who respond well to inﬂiximab therapy and who are
more likely to achieve remission. A larger randomised trial would
be necessary to further test this hypothesis.
This report demonstrates the efﬁcacy of TNFa blockade with
inﬂiximab in treatment-resistant scleritis. This study, however,
is limited by its retrospective nature, lack of a control group,
relatively small number of patients and limited follow-up period
for some patients. Further clinical studies, in particular rando-
mised clinical trials, are needed to investigate the potential
impact of anti-TNF-a therapy in scleritis.
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